8 terminated. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 8 |
| Phase 1 | 1 | Terminated 1 |
Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection. RV521, Placebo - Respiratory Syncytial Virus (RSV), Lower Resp Tract Infection | Phase 2 | Terminated | Pfizer | 51 | 2019-11-13 | 2024-10-23 |
| A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough BLU-5937, Placebo - Chronic Refractory Cough | Phase 2 | Terminated | Bellus Health Inc. - a GSK company | 68 | 2019-07-10 | 2021-08-03 |
| A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF RVT-1601, Placebo - Persistent Cough in IPF, Chronic Cough | Phase 2 | Terminated | Respivant Sciences GmbH | 108 | 2019-03-29 | 2020-06-11 |
| A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough GSK2798745, Placebo - Cough | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 17 | 2018-04-05 | 2019-10-02 |
| Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients QCC374 - Pulmonary Arterial Hypertension | Phase 2 | Terminated | Novartis Pharmaceuticals | 5 | 2018-02-01 | 2021-01-05 |
| Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients QCC374, Placebo Matching - Pulmonary Arterial Hypertension | Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2017-09-19 | 2021-01-05 |
| Phase II Open-Label Pilot Study of V3381 in Chronic Cough Indantadol - Cough | Phase 2 | Terminated | Vernalis (R&D) Ltd | 12 | 2009-10-01 | 2011-07-25 |
| Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis interferon-alpha lozenges, placebo lozenges - Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis | Phase 2 | Terminated | Ainos, Inc. (f/k/a Amarillo Biosciences Inc. | 1 | 2008-06-01 | 2012-04-24 |
Chronic Cough (5) · Dizziness (2) · Dyspnea (2) · Hypertension, Pulmonary (2) · Pulmonary Arterial Hypertension (2) · Syncope (2) · Pulmonary Disease, Chronic Obstructive (1) · Pulmonary Fibrosis (1) · Respiratory Sounds (1) · Rhinitis (1)
Pathological Conditions, Signs and Symptoms (8) · Respiration Disorders (8) · Respiratory Tract Diseases (8) · Signs and Symptoms (8) · Signs and Symptoms, Respiratory (8) · Lung Diseases (3) · Cardiovascular Diseases (2) · Consciousness Disorders (2) · Hypertension (2) · Nervous System Diseases (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2) · Sensation Disorders (2) · Unconsciousness (2) · Vascular Diseases (2)
BLU-5937 (1) · GSK2798745 (1) · Interferon-alpha (1) · indantadol (1) · sisunatovir (1)
Novartis Pharmaceuticals (2) · Ainos, Inc. (f/k/a Amarillo Biosciences Inc. (1) · Bellus Health Inc. - a GSK company (1) · GlaxoSmithKline (1) · Pfizer (1) · Respivant Sciences GmbH (1) · Vernalis (R&D) Ltd (1)
United Kingdom (7) · United States (5) · Germany (3) · Canada (2) · New Zealand (2) · South Korea (2) · Argentina (1) · Australia (1) · Belgium (1) · Chile (1) · Costa Rica (1) · Czechia (1) · Hungary (1) · Israel (1) · Italy (1)
Ahmet Tutuncu, MD, PhD (1) · Ashley Woodcock, Prof. (1) · Jacky Smith, MD, Ph.D. (1) · Lorenz O Lutherer, MD, PhD (1)
2016 (1), 2017 (1), 2019 (1)